Literature DB >> 32329874

Overexpression of ACE2 prevents hypoxia-induced pulmonary hypertension in rats by inhibiting proliferation and immigration of PASMCs.

H-H Hu1, R-F Zhang, L-L Dong, E-G Chen, K-J Ying.   

Abstract

OBJECTIVE: Imbalance of the ratio of angiotensin converting enzyme (ACE) and ACE2 may lead to pathological conditions in lung. However, its effect on hypoxia-induced pulmonary hypertension (HPH) remains unclear. Therefore, the aim of this study was to investigate the effects of ACE2 overexpression on rat primary pulmonary arterial smooth muscle cells (PASMCs) and HPH rat model.
MATERIALS AND METHODS: ACE and ACE2 expression in rat PASMCs under hypoxia condition, as well as in HPH rat model, was detected. The overexpressed ACE2 gene was transfected into PASMCs by Lentiviral. Later, the proliferation and migration of PASMCs were evaluated. Meanwhile, the overexpressed ACE2 gene was transfected into rats and exposed to hypoxia for four weeks. Finally, the right ventricular systolic pressure, the right ventricular hypertrophy, and the percentage of the medial wall thickness were measured to evaluate the development of HPH.
RESULTS: Imbalance of the expression of ACE/ACE2 was indicated in rat PASMCs under hypoxia condition and in the HPH rat model, respectively. The overexpression of ACE2 significantly inhibited PASMCs proliferation and migration. Moreover, the overexpressed ACE2 could significantly attenuate pulmonary hypertension, pulmonary vascular remodeling, and right ventricular hypertrophy in HPH rat model.
CONCLUSIONS: ACE2 is related to the formation of pulmonary vascular remodeling and pulmonary hypertension. Furthermore, it may prevent hypoxia-induced pulmonary hypertension by inhibiting the proliferation of PASMCs.

Entities:  

Year:  2020        PMID: 32329874     DOI: 10.26355/eurrev_202004_20867

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  5 in total

1.  Activation of Angiotensin-converting Enzyme 2 Protects Against Lipopolysaccharide-induced Glial Activation by Modulating Angiotensin-converting Enzyme 2/Angiotensin (1-7)/Mas Receptor Axis.

Authors:  Priya Tiwari; Virendra Tiwari; Shivangi Gupta; Shubha Shukla; Kashif Hanif
Journal:  Mol Neurobiol       Date:  2022-10-17       Impact factor: 5.682

2.  Clinical Characteristics and Outcomes of Hypertensive Patients Infected with COVID-19: A Retrospective Study.

Authors:  Liqin Chen; Jiankun Chen; Yuwan Wu; Jinyao Zhong; Fuzhen Zhou; Yuntao Liu; Aiting Xu; Jiqiang Li; Huayang Cai
Journal:  Int J Gen Med       Date:  2021-08-17

Review 3.  Alternative RAS in Various Hypoxic Conditions: From Myocardial Infarction to COVID-19.

Authors:  Tomas Rajtik; Peter Galis; Linda Bartosova; Ludovit Paulis; Eva Goncalvesova; Jan Klimas
Journal:  Int J Mol Sci       Date:  2021-11-26       Impact factor: 5.923

4.  Considerations for target oxygen saturation in COVID-19 patients: are we under-shooting?

Authors:  Niraj Shenoy; Rebecca Luchtel; Perminder Gulani
Journal:  BMC Med       Date:  2020-08-19       Impact factor: 8.775

Review 5.  Interplay of COVID-19 and cardiovascular diseases in Africa: an observational snapshot.

Authors:  Graham Chakafana; Daniel Mutithu; Julian Hoevelmann; Ntobeko Ntusi; Karen Sliwa
Journal:  Clin Res Cardiol       Date:  2020-08-18       Impact factor: 6.138

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.